POLD1-related polyposis and colorectal cancer syndrome
diseaseOn this page
Summary
POLD1-related polyposis and colorectal cancer syndrome (MONDO:0100351) is a cancer caused by POLD1 (GenCC Definitive), with 1 cohort gene (1 CIViC-evidence somatic driver).
At a glance
- Classification: Cancer
- Causal gene: POLD1 (GenCC Definitive)
- Cohort genes: 1
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | POLD1-related polyposis and colorectal cancer syndrome |
| Mondo ID | MONDO:0100351 |
| GARD | 0026151 |
| Is cancer (heuristic) | yes |
Data availability: 2 GenCC gene-disease records.
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › polyp › neoplastic polyp › polyposis › POLD1-related polyposis and colorectal cancer syndrome
Related subtypes (3): polyposis, intestinal, scattered and discrete, gastric adenocarcinoma and proximal polyposis of the stomach, POLE-related polyposis and colorectal cancer syndrome
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 15 · Orphanet: 3 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
Somatic driver evidence (intOGen + CIViC, cohort fanout)
| Gene | intOGen role | Cancer types | CIViC |
|---|---|---|---|
| POLD1 | LoF | BRCA,ESCA | CIViC #4384 |
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| POLD1 | Definitive | Autosomal dominant | POLD1-related polyposis and colorectal cancer syndrome | 15 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| POLD1 | Orphanet:363649 | Mandibular hypoplasia-deafness-progeroid features-lipodystrophy syndrome |
| POLD1 | Orphanet:440437 | Familial colorectal cancer Type X |
| POLD1 | Orphanet:447877 | Polymerase proofreading-related polyposis |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| POLD1 | HGNC:9175 | ENSG00000062822 | P28340 | DNA polymerase delta catalytic subunit | gencc |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| POLD1 | DNA polymerase delta catalytic subunit | As the catalytic component of the trimeric (Pol-delta3 complex) and tetrameric DNA polymerase delta complexes (Pol-delta4 complex), plays a crucial role in high fidelity genome replication, including in lagging strand synthesis, and repair. |
Protein-family classification
Druggable: 0 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Transcription factor | 1 | 8.3× | 0.121 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| POLD1 | Transcription factor | no | 2.7.7.7 | DNA-dir_DNA_pol_B_exonuc, DNA-dir_DNA_pol_B_multi_dom, DNA-dir_DNA_pol_B |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| mucosa of transverse colon | 1 |
| primordial germ cell in gonad | 1 |
| ventricular zone | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| POLD1 | 134 | ubiquitous | marker | mucosa of transverse colon, ventricular zone, primordial germ cell in gonad |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| POLD1 | 4,000 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| POLD1 | P28340 | 6 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 18. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Processive synthesis on the lagging strand | 1 | 1142.0× | 0.003 | POLD1 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 1 | 815.7× | 0.003 | POLD1 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 1 | 815.7× | 0.003 | POLD1 |
| Polymerase switching | 1 | 815.7× | 0.003 | POLD1 |
| Removal of the Flap Intermediate | 1 | 815.7× | 0.003 | POLD1 |
| Processive synthesis on the C-strand of the telomere | 1 | 761.3× | 0.003 | POLD1 |
| Telomere C-strand (Lagging Strand) Synthesis | 1 | 761.3× | 0.003 | POLD1 |
| Cytosolic iron-sulfur cluster assembly | 1 | 761.3× | 0.003 | POLD1 |
| Removal of the Flap Intermediate from the C-strand | 1 | 634.4× | 0.003 | POLD1 |
| PCNA-Dependent Long Patch Base Excision Repair | 1 | 519.1× | 0.003 | POLD1 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | 1 | 439.2× | 0.004 | POLD1 |
| Polymerase switching on the C-strand of the telomere | 1 | 423.0× | 0.004 | POLD1 |
| Recognition of DNA damage by PCNA-containing replication complex | 1 | 380.7× | 0.004 | POLD1 |
| Termination of translesion DNA synthesis | 1 | 346.1× | 0.004 | POLD1 |
| Dual Incision in GG-NER | 1 | 259.6× | 0.005 | POLD1 |
| HDR through Homologous Recombination (HRR) | 1 | 190.3× | 0.006 | POLD1 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | 1 | 178.4× | 0.006 | POLD1 |
| Dual incision in TC-NER | 1 | 173.0× | 0.006 | POLD1 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| DNA replication proofreading | 1 | 5617.3× | 0.001 | POLD1 |
| error-free translesion synthesis | 1 | 3370.4× | 0.001 | POLD1 |
| nucleotide-excision repair, DNA gap filling | 1 | 2808.7× | 0.001 | POLD1 |
| base-excision repair, gap-filling | 1 | 1123.5× | 0.002 | POLD1 |
| DNA synthesis involved in DNA repair | 1 | 936.2× | 0.002 | POLD1 |
| fatty acid homeostasis | 1 | 936.2× | 0.002 | POLD1 |
| DNA biosynthetic process | 1 | 802.5× | 0.002 | POLD1 |
| DNA-templated DNA replication | 1 | 561.7× | 0.003 | POLD1 |
| response to UV | 1 | 366.4× | 0.004 | POLD1 |
| cellular response to UV | 1 | 295.6× | 0.004 | POLD1 |
| DNA replication | 1 | 165.2× | 0.007 | POLD1 |
| DNA repair | 1 | 63.8× | 0.016 | POLD1 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| POLD1 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 1.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| POLD1 | 8 | Binding:8 |
Cohort enzymes (BRENDA EC)
| Symbol | EC numbers | Names |
|---|---|---|
| POLD1 | 2.7.7.7 | DNA-directed DNA polymerase |
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Drug repurposing candidates
0 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 1 | POLD1 |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| POLD1 | 8 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: POLD1